Incannex Healthcare Inc. reported financial results for the fiscal year ended June 30, 2025. Revenue from customers was $0.086 million, representing an increase of approximately 617% compared to $0.012 million in the prior year. The growth in revenue was primarily attributed to the expansion of rehabilitation services provided to clinic patients. The company reported a net loss of $46.89 million for the year, compared to a net loss of $18.46 million in the previous fiscal year, reflecting an increase in comprehensive losses. Total operating expenses decreased by 21% to $23.88 million from $30.05 million in the prior year, with research and development expenses at $10.75 million and general and administrative expenses at $13.13 million. Incannex Healthcare stated that it has not generated any revenue from product sales and does not expect to generate material revenues unless and until its drug candidates advance to later stages of development. The company expects to incur substantial and increasing losses in the future as it expands its research and development activities.